Headlands Technologies’s Recursion Pharmaceuticals RXRX Stock Holding History

Headlands Technologies’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.42M	Sell	387,749 -40,090	-9%	-$133K	0.15%	165
2026 Q1	$1.31M	Buy	427,839 +196,367	+85%	+$759K	0.15%	157
2025 Q4	$947K	Buy	231,472 +42,351	+22%	+$210K	0.08%	277
2025 Q3	$923K	Sell	189,121 -10,294	-5%	-$54.1K	0.07%	253
2025 Q2	$1.01M	Buy	199,415 +33,565	+20%	+$165K	0.12%	178
2025 Q1	$877K	Buy	165,850 +76,536	+86%	+$558K	0.1%	207
2024 Q4	$604K	Buy	89,314 +59,211	+197%	+$398K	0.06%	309
2024 Q3	$198K	Buy	30,103 +7,011	+30%	+$50.3K	0.02%	523
2024 Q2	$173K	Buy	+23,092	New	+$201K	0.02%	511

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Headlands Technologies's RXRX Position: Q2 2026 in Review

Headlands Technologies reduced its Recursion Pharmaceuticals (RXRX) stake by 9.4% in Q2 2026, selling an estimated $133K and leaving 387,749 shares worth $1.42M. The position accounts for 0.15% of the portfolio, ranked #165.

Headlands Technologies first reported a position in RXRX in Q2 2024 and has held it in 9 quarters since. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Headlands Technologies held 387,749 shares of Recursion Pharmaceuticals worth $1.42M as of Q2 2026.
Headlands Technologies sold 40,090 Recursion Pharmaceuticals shares in Q2 2026, an estimated $133K.
Recursion Pharmaceuticals made up 0.15% of Headlands Technologies's portfolio in Q2 2026, its #165 holding.
Headlands Technologies first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.